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Abstract
Palmitoylation of the neuronal plasticity protein GAP-43 has previously been shown to occur at the plasma membrane,
but the site of initial palmitoylation has not been identified. To identify this organelle we have incubated GAP-43 with
various subcellular fractions and have analyzed palmitoylation by the Triton X-114 partitioning method. In vitro-translated
[35S]methionine-labeled GAP-43 was incubated with plasma membrane, nuclei, mitochondria, Golgi apparatus and a rough
microsome preparation that contained the ER-Golgi intermediate compartment (ERGIC), but not plasma membrane or
Golgi apparatus. GAP-43 partitioned into Triton X-114 in the presence of plasma membrane, Golgi, and ERGIC
membranes, but not nuclei or mitochondria. Partitioning caused by the ERGIC was blocked by pretreatment of the
membranes with the palmitoylation inhibitors dithiothreitol, tunicamycin, and low temperature, and by treatment of
GAP-43 with iodoacetamide. The time course of partitioning agreed closely with the time course of incorporation of
radioactive palmitate into proteins as reported previously. Because the ERGIC has a broad distribution in the cell, our
results provide evidence that the ERGIC is the initial site of GAP-43 palmitoylation. ß 1999 Elsevier Science B.V. All
rights reserved.
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1. Introduction
GAP-43, also known as B-50, F1, neuromodulin
and P57, is an intracellular protein that is present at
a higher level in developing as opposed to adult neu-
rons and thus may function in the mechanism of
neurite outgrowth [1^4]. The protein also occurs in
certain parts of the normal adult central nervous
system, including the cerebral cortex, hippocampus,
cerebellum, and retina and is thought to play a role
in modulating neurotransmission and neural plasti-
city at these sites [1].
GAP-43 undergoes fast axonal transport from the
cell body to its ¢nal destination at the growth cone
plasma membrane in developing neurons and the
presynaptic membrane in adult neurons [4]. Proteins
undergoing fast axonal transport have been shown
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by immuno£uorescence microscopy studies to be lo-
calized initially at the Golgi apparatus [5,6]. We
would like to know if GAP-43 palmitoylation can
occur at this site or prior to this site. There are
only three known sites of protein palmitoylation in
animal cells: the ER-Golgi intermediate compart-
ment (ERGIC) between the rough ER and Golgi
apparatus and which is now known to correspond
to ER export sites called vesicular-tubular clusters
(VTCs) [7^11], the Golgi apparatus itself [12,13]
and speci¢cally the cis Golgi network (CGN) since
palmitoylation occurs before the cis Golgi [14], and
the plasma membrane [15,16]. GAP-43 is not an in-
tegral membrane protein, but associates with the
plasma membrane following palmitoylation at Cys-
3 and Cys-4 by a plasma membrane palmitoyltrans-
ferase [15]. Palmitoylation at Cys-4 is critical for
membrane association [17]. Since GAP-43 travels
down the axon in a membrane-bound form [4], it is
possible that palmitoylation initially occurs in the
neuronal cell body. The ERGIC is a likely ¢rst site
for GAP-43 palmitoylation since it is distributed
throughout the cell while the Golgi apparatus is
mainly perinuclear [7,8,14]. GAP-43 emerging from
synthesis on free ribosomes throughout the cell body
would thus be more likely to encounter the ERGIC
than the Golgi apparatus. The ERGIC would then
deliver membrane-bound GAP-43 to the Golgi.
COS-7 cells transfected with GAP-43 cDNA concen-
trated GAP-43 immunoreactivity at the Golgi appa-
ratus and it was suggested that this is the site at
which GAP-43 ¢rst becomes palmitoylated [18]. It
was also suggested that GAP-43 could be sorted
to the Golgi apparatus by its a⁄nity for the Golgi
palmitoyltransferase [18]. We provide evidence
that GAP-43 is palmitoylated by a preparation
of rough microsomes containing the ERGIC and
by Golgi apparatus isolated from canine pancreas.
This organ is a rich source of organelles and their
use appears justi¢ed given the high degree of con-
servation that exists in ER-Golgi membrane £ow
in cells as divergent as yeast and neurons [19]. Be-
cause of this conservation, sorting mechanisms ap-
pear to be the same in neuronal and non-neuronal
cells [20]. Useful sorting results at the level of
the Golgi apparatus have therefore been obtained
for GAP-43 using non-neuronal cells like COS-7
[18].
2. Materials and methods
2.1. Materials
GAP-43 cDNA was kindly supplied by Dr. J.H.P.
Skene, Duke University Medical Center. Antibody to
rat ERGIC53/p58 was provided by Dr. Jaakko Sar-
aste, University of Bergen. [35S]Methionine, UDP-
galactose [galactose-4,5-3H(N)], Enlightning, and Re-
£ection autoradiography ¢lm were from Dupont,
Wilmington, DE. Tunicamycin and clone 91E12
mouse monoclonal anti-GAP-43 were obtained
from Boehringer Mannheim, Indianapolis, IN. Rab-
bit reticulocyte lysate and enzymes used in cell-free
translation were obtained from Promega, Madison,
WI, except HindIII, which was from New England
Biolabs. Triton X-114 was from Calbiochem and
NCS II tissue solubilizer was from Amersham. Cy-
cloheximide, UDP-galactose, palmitoyl CoA, iodo-
acetamide, and triethanolamine were from Sigma,
St. Louis, MO. Sucrose, EDTA, DTT, AG501-X8
resin and all materials used in SDS-PAGE were
from Bio-Rad, Hercules, CA.
2.2. Isolation of a plasma membrane preparation and
a rough microsome preparation containing the
ERGIC
Rough microsomes were isolated from canine pan-
creas following Potter^Elvehjem homogenization as
described [21]. We have found that this preparation
also contains the ERGIC, but does not contain Gol-
gi apparatus or plasma membrane. All centrifuga-
tions were at 4‡C. The rough microsomes and ER-
GIC were puri¢ed from plasma membrane-derived
vesicles present in a post-mitochondrial supernatant
by sedimentation through a 1.3 M sucrose cushion
containing 50 mM triethanolamine acetate (TEA)
(pH 7.5), 50 mM potassium acetate, 6 mM magne-
sium acetate, 1 mM EDTA, 1 mM DTT, and 1 mM
phenylmethylsulfonyl £uoride (PMSF). Centrifuga-
tion was for 2.5 h at 145 000Ugav (40 000 rpm) in a
Beckman 50.2 Ti rotor. Plasma membrane remained
at the top of the cushion and was resuspended in 5 ml
resuspension bu¡er (0.25 M sucrose, 50 mM TEA
(pH 7.5), 1 mM DTT). The pellet of rough micro-
somes containing the ERGIC was adjusted with re-
suspension bu¡er to a ¢nal volume of 30 ml and an
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A280 = 50, as measured in 1% SDS. All membrane
fractions were frozen in liquid nitrogen and stored
at 370‡C. The 1.3 M sucrose cushion allowed only
the ERGIC and rough microsomes to be present in
the pellet fraction, as determined by immunostaining
for the ERGIC marker protein ERGIC53/p58 and
enzymatic assay (see Section 3).
2.3. Preparation of nuclear, mitochondrial, and Golgi
fractions
Dog pancreas was homogenized as above for RM.
We then followed the method [22] used previously
for rat liver. All centrifugations were at 4‡C. The
homogenate was centrifuged at 600Ugav for 10
min. The pellet was resuspended in 15 ml resuspen-
sion bu¡er to obtain the nuclear fraction. The super-
natant was applied to the same 1.3 M sucrose cush-
ion as referred to above, followed by centrifugation
in a Beckman SW28 rotor for 2 h at 63 000Ugav
(22 000 rpm). The pelleted material was resuspended
in resuspension bu¡er and centrifuged at 10 000Ugav
for 10 min to obtain a mitochondrial pellet free of
Golgi apparatus and rough microsomes. The materi-
al at the top of the cushion contained Golgi appara-
tus and was pooled and layered on 8 ml of 1.25 M
sucrose. On top of this was placed 7 ml of 1.0 M
sucrose, followed by 5 ml of 0.5 M sucrose. All su-
crose solutions also contained 50 mM TEA (pH 7.5),
50 mM potassium acetate, 6 mM magnesium acetate,
1 mM EDTA, 1 mM DTT, and 1 mM PMSF. The
step gradient was centrifuged for 90 min at
83 000Ugav (25 000 rpm). Puri¢ed Golgi apparatus
were recovered at the 1.0/0.5 M sucrose interface.
They were then adjusted to 0.25 M sucrose and 0.2
M NaCl and centrifuged for 30 min at 167 000Ugav
(43 000 rpm) in a Beckman 50.2 Ti rotor. The pel-
leted Golgi were resuspended by Dounce homogeni-
zation (¢ve strokes using a tight pestle) in 4 ml of
0.25 M sucrose, 50 mM TEA (pH 7.5), 1 mM DTT
and were frozen in liquid nitrogen and stored at
370‡C. The A280 of the suspension was determined
in 1% SDS and was found to be 27.
2.4. Enzymatic characterization of subcellular
fractions
We assayed for the trans Golgi marker enzyme
UDP-galactose:N-acetylglucosamine galactosyltrans-
ferase [23]. To 1.4 mg of UDP-galactose was added
1.4 ml water and 20 Wl (1.7U106 CPM) of UDP-
galactose [galactose-4,5-3H(N)] in ethanol/water 7:3
(v/v). Three hundred microliters of this solution was
mixed with 300 Wl 0.3 M MnCl2, 300 Wl 30 mM L-
mercaptoethanol in water, and 600 Wl 40 mM
HEPES-NaOH (pH 7.0). The mixture was divided,
and tube A received 150 Wl water, while tube B re-
ceived 150 Wl of 0.4 M N-acetylglucosamine in water.
Ten microliters of the membrane suspension to be
assayed was mixed with 60 Wl from tube A and
with 60 Wl from tube B. The tubes were incubated
for 30 min at 37‡C. Each tube then received 30 Wl
0.2 M EDTA (pH 7.5) and 1 ml water, followed by
application to a 2-cm column of AG501-X8 mixed
bed ion exchange resin (20^50 mesh) equilibrated
with water in a Pasteur pipette. The £ow-through
was collected and mixed with 10 ml Scintiverse II
scintillation £uid and the radioactivity was deter-
mined in a scintillation counter. Activity was ex-
pressed as CPM (tube B) 3CPM (tube A) divided
by the amount of protein added. We based our
protein concentrations on the relationship that
1 A280 unit represents a protein concentration of
1 mg/ml.
We also assayed for the plasma membrane marker
enzyme 5P-nucleotidase by measuring the release of
phosphate from AMP [24]. Membrane samples (50^
200 Wg protein) were incubated at 37‡C for zero and
20 min in the presence of AMP, MgCl2, and Tris-
HCl (pH 8.5). Aliquots were then mixed with ascor-
bic acid and ammonium molybdate and incubated at
45‡C for 20 min for phosphate determination. The
concentration of the colored complex that formed
was determined in the spectrophotometer at 820
nm. We found that neither our RM nor Golgi prep-
aration was contaminated with plasma membrane
using this assay.
2.5. Generation of in vitro-synthesized
[35S]methionine-labeled GAP-43
Full-length rat GAP-43 cDNA present on the vec-
tor pGEM3 was transcribed using T7 RNA polymer-
ase. The vector was ¢rst linearized by digestion with
HindIII. Following transcription, the DNA was di-
gested with RNase-free DNase, and the mRNA was
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puri¢ed by extraction with chloroform/phenol 1:1
and ethanol precipitation. The mRNA was not
capped and was found to be translated e⁄ciently in
the reticulocyte lysate translation system used previ-
ously [25]. The translation mixture contained L-
[35S]methionine (1200 Ci/mmol). GAP-43 contains
methionines at positions 1 and 5 only and appeared
on £uorographs with an apparent molecular mass of
43 kDa in its unpalmitoylated form. Each translation
mixture contained 17.5 Wl rabbit reticulocyte lysate,
0.5 Wl of amino acid mixture minus methionine (19
amino acids present at 1 mM each), 2 Wl L-
[35S]methionine (22 WCi, 18.3 pmol), 2.2 Wl of dieth-
ylpyrocarbonate (DEPC)-treated water, and 1 Wl of
0.1 mg/ml puri¢ed GAP-43 mRNA in DEPC-water.
We con¢rmed that the product was GAP-43 by im-
munoprecipitation using mouse monoclonal anti-
GAP-43 (clone 91E12).
2.6. Assay for palmitoylation: incubation of
[35S]methionine-labeled GAP-43 with
membranes followed by Triton X-114
extraction
We performed this palmitoylation assay as previ-
ously described [15,16,26,27]. Translation mixtures
(23.2 Wl) were blocked after a 20-min incubation at
30‡C by the addition of 2 Wl of 25 mM cycloheximide
in water and were then added to 25 Wl of either
plasma membrane, nuclei, mitochondria, rough mi-
crosomes, or Golgi membrane. The mixtures were
incubated at 30‡C for 45 min. The samples were
then centrifuged for 6 min in an Airfuge (Beckman
Instruments, Palo Alto, CA) at 30 psi using an A-
100/30 rotor. Five microliters of each supernatant
was mixed with 45 Wl SDS sample bu¡er (see [25]
for composition). Each membrane pellet received 1
ml of 1% (w/v) Triton X-114, 10 mM Tris-HCl (pH
7.4), 150 mM NaCl on ice, as described [26]. The
pellets were dissolved and the solutions were placed
at 30‡C for 2 min. The cloudy solution was then
centrifuged 2 min at 16 000Ug in a microcentrifuge.
The pellet fraction contained Triton X-114 and re-
ceived 50 Wl SDS sample bu¡er followed by boiling
5 min. The supernatants and Triton X-114 pellets
were then analyzed by SDS-PAGE and £uorogra-
phy.
2.7. Pretreatment with tunicamycin, dithiothreitol,
iodoacetamide, and low temperature
Tunicamycin, as a mixture of di¡erent chain
lengths, was dissolved at 10 mg/ml in 10 mM
NaOH and its concentration was con¢rmed by the
relationship that 10 Wg/ml tunicamycin yields an A260
of 0.12 [16]. Membrane suspension to be assayed (25
Wl) received 6 Wl of 10 mg/ml tunicamycin, followed
by incubation at 30‡C for 5 min. After addition of
the translation mixture (25.2 Wl) a ¢nal tunicamycin
concentration of 1.07 mg/ml was achieved. Control
membranes received 6 Wl of 10 mM NaOH. The pH
was not a¡ected by these additions. Mixtures were
incubated 45 min at 30‡C, followed by the prepara-
tion of pellet and supernatant fractions as above.
The pellet fraction was then treated with Triton X-
114 as described above. Either in vitro synthesized
GAP-43 or 25 Wl RM were treated with 6.8 mM
iodoacetamide for 10 min at room temperature fol-
lowed by quenching with 10 mM DTT. DTT was
added to mixtures as described in Fig. 7. Mixtures
were also incubated on ice as described [13] prior to
the addition of Triton X-114.
2.8. Determination of radioactivity
We determined the radioactivity present in gels by
overlaying with the £uorograph and cutting out the
dried gel section. The gel sections were rehydrated
for 1 h in 100 Wl of water and were then incubated
in 1 ml of NCS II tissue solubilizer/water, 9:1 (v/v)
for 6 h at 50‡C. After cooling, 50 Wl of glacial acetic
acid was added followed by 10 ml of Scintiverse II
scintillation £uid. Radioactivity was determined in a
Packard model 1600 TR liquid scintillation counter.
2.9. SDS-polyacrylamide gel electrophoresis
(SDS-PAGE) and £uorography
SDS-PAGE was performed using 12% polyacryl-
amide gels as described [25] except that the gels were
run for 17 h at room temperature and at a constant
current of 12 mA. The gels were then treated with
Enlightning, dried, and exposed to autoradiography
¢lm at 370‡C for 1^3 days. The ¢lm was developed
using Kodak GBX developer and ¢xer.
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2.10. Immunoblotting and immunoprecipitation
Both procedures were performed as described [15].
Some gels had proteins transferred to nitrocellulose
which was then probed with rat antibody to ER-
GIC53/p58. Results were visualized using horserad-
ish peroxidase-labeled goat anti-rat IgG and chemi-
luminescence.
3. Results
3.1. The ER-Golgi intermediate compartment
(ERGIC) is present in the rough microsome
preparation
Fig. 1 is an immunoblot that detects the presence
Fig. 1. The ER-Golgi intermediate compartment (ERGIC) is
present in the rough microsome preparation. The ¢gure shows
an immunoblot of a gel that contained no membranes (lane 1),
50 Wg of RM protein (lane 2), 25 Wg of RM protein (lane 3),
and 27 Wg of Golgi protein (lane 4). The blot was probed with
rat antibody to the ERGIC marker protein ERGIC53/p58. Re-
sults were visualized using a horseradish peroxidase-labeled
goat anti-rat second antibody followed by chemiluminescence.
The protein is detected at 58 kDa. Equal aliquots of RM and
Golgi membranes displayed approximately equal ERGIC53/p58
immunoreactivity, but a 7.5-fold greater volume of RM than
Golgi was isolated. Most of the ERGIC was therefore present
in the RM.
Fig. 2. Palmitoylation assay: both ERGIC and Golgi apparatus
cause GAP-43 to partition into Triton X-114 and this e¡ect is
blocked by tunicamycin. Both RM and Golgi apparatus were
incubated with in vitro-synthesized [35S]methionine-labeled
GAP-43 in the presence and absence of tunicamycin. Incuba-
tions were for 45 min at 30‡C. Odd-numbered lanes represent
5 Wl aliquots of supernatants obtained following sedimentation of
the membranes while even-numbered lanes represent Triton X-
114 pellet fractions obtained after dissolving membrane pellets
in Triton X-114 solution. The position of GAP-43 is shown by
the 45-kDa molecular weight marker. Lanes 4 and 8 show that
RM and Golgi, respectively, cause GAP-43 to be present in
Triton X-114. Lane 2 shows that no partitioning occurs in the
absence of membranes. Lanes 6 and 10 show that tunicamycin
blocks the entry of GAP-43 into Triton X-114 pellet fractions
caused by RM and Golgi, respectively.
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of the intermediate compartment marker protein ER-
GIC53/p58 in both the rough microsome and Golgi
fractions. Other membrane fractions were negative.
Lane 1 shows that no labeled band at 58 kDa is
obtained if membranes were not present. The blot
also shows that about the same amount of ER-
GIC53/p58 was present in an equal aliquot of RM
and Golgi (compare lanes 2 and 4). When half the
amount of RM protein was applied, a signal about
half as strong was obtained at 58 kDa (lane 3). The
total amount of ERGIC53/p58 isolated with RM was
7.5 times greater than Golgi since the RM were
present in a 7.5-fold greater volume of resuspension
bu¡er than Golgi. Assay for 5P-nucleotidase and gal-
actosyltransferase (see Fig. 3) con¢rmed that the RM
were free of both plasma membrane and Golgi ap-
paratus.
3.2. Palmitoylation assay: both ERGIC and Golgi
apparatus cause GAP-43 to partition into Triton
X-114 and the e¡ect is blocked by tunicamycin
The Triton X-114 assay for palmitoylation is
well established and we performed it as described
[15,16,26,27]. Fig. 2 shows that partitioning of
GAP-43 into Triton X-114 pellet fractions is caused
by both the Golgi and RM preparations. Translation
mixtures were incubated in the presence and absence
of membranes as indicated at the top of the gel,
centrifuged, and divided into supernatant and pellet
fractions. The supernatant fractions were directly an-
alyzed (odd-numbered lanes) while the pellet frac-
tions were treated with Triton X-114 solution and
centrifuged again. These pellets contained material
that had partitioned into Triton X-114 and are
shown in the even-numbered lanes. The position of
GAP-43 is shown by the 45 kDa molecular weight
marker. Lanes 1 and 2 show that all of the synthe-
sized GAP-43 occurred in the initial supernatant if
no membranes were present. The remaining lanes
show that the presence of membranes caused GAP-
43 to be present in membrane pellets and to subse-
quently partition into Triton X-114. The RM prep-
aration modi¢ed the GAP-43 so that it partitioned
into Triton X-114 (lane 4). Pretreatment of RM with
tunicamycin diminished the presence of GAP-43 in
the Triton X-114 pellet (lane 6). In the presence of
Golgi membranes GAP-43 was also modi¢ed such
that it partitioned into Triton X-114 (lane 8). As
with RM, pretreatment of the Golgi membranes
Fig. 3. Quantitation of GAP-43 partitioning into Triton X-114
caused by RM and Golgi preparations. The bands correspond-
ing to GAP-43 in lanes 4 and 8 of Fig. 2 were cut out and
their radioactivity determined to establish how much GAP-43
was made to partition into Triton X-114 by RM and Golgi, re-
spectively. These values were divided by the amount of protein
present in each incubation and were determined to be 5674
CPM/mg for RM and 3451 CPM/mg for Golgi (black bars).
Galactosyltransferase activity (a Golgi marker) was measured as
described in Section 2 for both RM and Golgi preparations
(gray bar).
Fig. 4. Plasma membrane, but not nuclei or mitochondria,
cause GAP-43 to partition into Triton X-114. Lanes 1^3 repre-
sent Triton X-114 pellet fractions. Lanes 1 and 2 show that in-
cubation of in vitro-synthesized GAP-43 with 25 Wl aliquots of
nuclei and mitochondria, respectively, did not yield GAP-43 in
the Triton X-114 pellet. Lane 3 shows that inclusion of 25 Wl
of plasma membrane fraction did result in partitioning. Adja-
cent lanes contained radioactive GAP-43 in the absence of
membranes to mark the position of the protein at 45 kDa.
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with tunicamycin diminished the amount of GAP-43
that partitioned into Triton X-114 (lane 10).
3.3. Quantitation of GAP-43 partitioning into Triton
X-114
Fig. 3 compares RM and Golgi apparatus accord-
ing to galactosyltransferase activity (a trans Golgi
marker) and the ability to modify GAP-43 such
that it partitions into Triton X-114. It can be seen
that the RM contain negligible galactosyltransferase
activity and hence Golgi contamination, whereas the
puri¢ed Golgi give a very strong signal for galacto-
syltransferase. Fig. 3 shows that on a per mg protein
basis the RM are more active than the Golgi in caus-
ing GAP-43 to partition into Triton X-114.
3.4. Plasma membrane, but not nuclei or
mitochondria, cause GAP-43 to partition into
Triton X-114
Fig. 4 shows that neither nuclei (lane 1) or mito-
chondria (lane 2) caused GAP-43 to partition into
Triton X-114. By contrast, plasma membrane (lane
3) did cause GAP-43 to partition. The latter result is
consistent with previous work [16] it which it was
shown that neuronal growth cone plasma membrane
catalyzes the palmitoylation of GAP-43.
3.5. Time course of GAP-43 partitioning
Fig. 5 shows that the maximum partitioning of
GAP-43 into Triton X-114 occurred after a 20-min
incubation of GAP-43 with ERGIC membranes.
Longer incubation times yielded less GAP-43 in the
Triton X-114 pellet. This result agrees closely with
the time course of incorporation of radioactive pal-
mitate into the proteins of heart subcellular fractions
[28]. Optimum palmitoylation occurred at 30 min,
with longer incubation times producing lower levels
of palmitoylation [28]. Similarly, palmitoylation of
the L2-adrenergic receptor in cultured cells reached
a maximum at 1 h incubation but longer incubation
times produced a markedly lower yield of palmitoy-
lated protein [29]. All of these results may re£ect the
turnover of the palmitoylation reaction.
3.6. Iodoacetamide treatment of GAP-43 blocks
partitioning
Iodoacetamide reacts with protein sulfhydryl
Fig. 5. Time course of GAP-43 partitioning. In vitro-synthe-
sized GAP-43 was incubated with 25 Wl RM suspension for in-
creasing periods of time at 30‡C. The RM were sedimented and
extracted with Triton X-114. The Triton X-114 pellets were
then analyzed by SDS-PAGE and £uorography. The radioac-
tive bands were cut out and their radioactivity determined, as
shown by the circles. The maximum amount of GAP-43 present
in the Triton X-114 pellet was obtained after a 20-min incuba-
tion.
Fig. 6. Iodoacetamide treatment of GAP-43 blocks partitioning.
In vitro-synthesized GAP-43 was incubated with either no
membranes (lanes 1 and 2), 25 Wl RM (lanes 3 and 4), or 25 Wl
RM that had been treated with iodoacetamide (IAA) (lanes 7
and 8). GAP-43 that had been treated with IAA was incubated
with 25 Wl RM (lanes 5 and 6). Supernatants (odd-numbered
lanes) and Triton X-114 pellets (even-numbered lanes) are
shown. IAA treatment of GAP-43 inhibited partitioning (lane
6) while IAA treatment of RM had no e¡ect (lane 8).
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groups and would be expected to block partitioning
of GAP-43 into Triton X-114 if this partitioning
were due to the thioesteri¢cation of Cys-3 and Cys-
4 with palmitate. Fig. 6 shows that treatment of
GAP-43 with iodoacetamide (lane 6) does inhibit
ERGIC-induced partitioning of GAP-43 when com-
pared with the control (lane 4). Treatment of the
membranes with iodoacetamide had no e¡ect on
GAP-43 partitioning (lane 8).
3.7. Dithiothreitol blocks GAP-43 partitioning
Fig. 7 shows that inhibition of ERGIC-induced
GAP-43 partitioning occurred when samples were
¢rst incubated with DTT at concentrations of 10.2
mM (lane 8) and 14.7 mM (lane 10). These results
agree with those obtained previously [12] in which it
was shown that palmitoyltransferase activity is inhib-
ited at these concentrations of DTT. This experiment
thus provides additional evidence that the partition-
ing that we are observing is due to GAP-43 palmi-
toylation.
3.8. Low temperature inhibits GAP-43 partitioning
Fig. 8 shows that incubation of GAP-43 with ER-
GIC membranes on ice prior to treatment with Tri-
ton X-114 (lane 3) inhibits the partitioning of GAP-
43 when compared with the control incubation car-
ried out at 30‡C (lane 2). No membranes were
present in the sample of lane 1. This result agrees
with those obtained previously [13] in which palmi-
toyltransferase activity was shown to be inhibited at
0‡C and provides additional evidence that the parti-
tioning that we observe is due to GAP-43 palmitoy-
lation.
3.9. Comparison of the e¡ect of tunicamycin and
palmitoyl CoA on GAP-43 partitioning
Fig. 9 compares the e¡ect of tunicamycin and pal-
mitoyl CoA on GAP-43 partitioning into Triton X-
114 caused by ERGIC membranes. In the presence
of tunicamycin (lane 4), GAP-43 partitioning is
blocked, whereas partitioning is not blocked in the
case of exogenously added palmitoyl CoA at a ¢nal
concentration of 10 WM (lane 6). The amount of
partitioning seen in lane 6 is the same as that seen
in the control lanes of Figs. 2 and 6. Palmitoyl CoA
at this concentration has been shown to be utilized
by a plasma membrane palmitoyltransferase [16].
4. Discussion
We would like to determine the initial site in the
Fig. 7. Dithiothreitol blocks GAP-43 partitioning. In vitro-syn-
thesized GAP-43 was incubated with 25 Wl RM in the presence
of DTT at a ¢nal concentration of 1.3 mM (lanes 1 and 2), 3.6
mM (lanes 3 and 4), 5.8 mM (lanes 5 and 6), 10.2 mM (lanes 7
and 8), and 14.7 mM (lanes 9 and 10). Supernatants (odd-num-
bered lanes) and Triton X-114 pellets (even-numbered lanes) are
shown. DTT at 10.2 mM (lane 8) and 14.7 mM (lane 10)
blocked GAP-43 partitioning into Triton X-114.
Fig. 8. Low temperature blocks GAP-43 partitioning. In vitro-
synthesized GAP-43 was incubated with RM for 30 min on ice
(lane 3) or at 30‡C (lane 2). Lane 1 received a sample that con-
tained no membranes. The RM were then sedimented and ex-
tracted with Triton X-114. Incubation on ice eliminated the
presence of GAP-43 in the Triton X-114 pellet.
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cell at which GAP-43 becomes palmitoylated. For
this purpose, we incubated in vitro-translated, radio-
active GAP-43 with various membrane fractions and
assayed for palmitoylation by the established method
of protein partitioning into Triton X-114
[15,16,26,27]. We ¢rst had to de¢ne the characteris-
tics of our membrane fractions. We immunostained
equal aliquots of both RM and Golgi preparations
for the ER-Golgi intermediate compartment marker
protein ERGIC53/p58 and found that each fraction
was equally immunopositive. However, we isolated
30 ml of RM suspension and only 4 ml of Golgi
suspension, so that the total amount of marker pro-
tein in the RM preparation was 7.5 times greater
than that in Golgi. This is consistent with the fact
that there is a larger distribution of ERGIC in the
cell than Golgi apparatus [14]. Our RM preparation
therefore contained most of the ERGIC, while the
Golgi preparation may contain primarily the ER-
GIC53/p58 protein itself that was cycled from the
ER to the Golgi. This cycling is known to occur
[30]. The density of the ERGIC is intermediate be-
tween that of rough ER and Golgi [10]. In our iso-
lation scheme, the ERGIC sedimented with rough
microsomes through the 1.3 M sucrose cushion,
which the Golgi apparatus and plasma membrane
cannot do. We con¢rmed the absence of Golgi and
plasma membrane in the RM by marker enzyme
assay. The only known palmitoylating activity that
our RM preparation can contain is therefore the
ERGIC.
We found that GAP-43 partitioned into Triton X-
114 in a membrane-dependent fashion in the case of
plasma membrane, ERGIC, and Golgi membranes,
but not nuclear or mitochondrial membranes. We
then focused on the ERGIC because it has a wide
distribution in the cell and would be a likely site for
the initial palmitoylation of GAP-43. The following
evidence suggests that partitioning re£ects the palmi-
toylation of GAP-43. GAP-43 has been shown to
partition into Triton X-114 and this partitioning is
due to the addition of the hydrophobic palmitate
chains [15]. The partitioning caused by the ERGIC
was blocked by pretreatment of the membranes with
tunicamycin, dithiothreitol, and low temperature.
Whereas tunicamycin is well known as an inhibitor
of N-linked glycosylation, it has also been shown to
block protein palmitoylation [16]. GAP-43 is not gly-
cosylated [3], so tunicamycin can only act on GAP-
43 at the level of palmitoylation. Dithiothreitol [12]
and low temperature [13] have also been shown to
inhibit protein palmitoylation. Iodoacetamide treat-
ment of GAP-43 blocked partitioning, and this com-
pound reacts with the sulfhydryl groups of GAP-43
that are the sites of palmitate addition. Additionally,
the time course of partitioning of GAP-43 into Tri-
ton X-114 revealed an optimum incubation time of
20 min. This result agreed very well with the time
course of incorporation of radioactive palmitate
into the proteins of heart subcellular fractions [28]
and the L2-adrenergic receptor [29]. In all of these
cases, longer incubation times produced a lower level
of palmitoylation, possibly as a result of turnover of
the palmitate attached to the protein. Finally, the
GAP-43 bands in the Triton X-114 pellets are at a
slightly higher molecular weight than the bands ob-
tained when membranes were absent (Figs. 2,6 and
7). This higher apparent molecular weight of GAP-
43 is consistent with the protein having been palmi-
toylated [15]. All of these results are consistent with
the action of an ERGIC palmitoyltransferase on
Fig. 9. Comparison of the e¡ects of tunicamycin and palmitoyl
CoA on GAP-43 partitioning. In vitro-synthesized GAP-43 was
incubated with 25 Wl RM in the presence of tunicamycin (lanes
1, 3, and 4) or 10 WM palmitoyl CoA (lanes 2, 5, and 6). The
mixtures were centrifuged and yielded supernatants (lanes 1 and
2). The pellets were extracted with Triton X-114 and centri-
fuged yielding a supernatant (lanes 3 and 5) and pellet (lanes 4
and 6). Tunicamycin blocked the presence of GAP-43 in the
Triton X-114 pellet (lane 4) but palmitoyl CoA did not (lane
6).
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GAP-43. It is possible that the ERGIC localization
of GAP-43 was not observed previously by immuno-
£uorescence microscopy [6,18] because incubation of
cultured cells at 15‡C is required to block ERGIC to
Golgi transport [7,8,14]. At higher temperatures
transport to the Golgi apparatus rapidly occurs
[7,8,14].
Patterson and Skene [16] showed that palmitoyla-
tion of GAP-43 by isolated neuronal growth cone
plasma membrane occurred readily in the presence
of exogenously added radioactive palmitoyl CoA.
When we made a similar attempt with ERGIC and
Golgi little or no labeling of GAP-43 occurred, even
though palmitoylation was readily detected by GAP-
43 partitioning into Triton X-114. Tunicamycin re-
sembles palmitoyl CoA in structure [16] and its in-
hibition of GAP-43 partitioning suggests that palmi-
toyl CoA is in some way involved in the GAP-43
palmitoylation that we have observed. Exogenously
added radioactive palmitoyl CoA may not be the
optimum substrate for the ERGIC palmitoyltransfer-
ase. For example, high levels of acyl CoA hydrolase
activity in the RM preparation could diminish the
availability of exogenously added palmitoyl CoA
for the ERGIC palmitoyltransferase. Palmitoyl
CoA generated from the membranes by enzymes
present in the reticulocyte lysate of the partitioning
assay may be more readily utilizable for protein
palmitoylation than exogenously added palmitoyl
CoA.
Our ¢ndings suggest that GAP-43 is initially
palmitoylated at the ERGIC and is then shuttled
forward to the Golgi apparatus, where it is concen-
trated. These interactions appear to be of consider-
able importance in the subsequent sorting of the pro-
tein to the plasma membrane.
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